Nucleic Acids Research · 2018 · 27 citations · 47 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyMolecular OncologyChemotherapy In Hematologic MalignanciesEnzymatic Cleavage StrategiesTargeted Cancer TherapyTargeted TherapyTopoisomerase InhibitorsAcute Promyelocytic LeukemiaCleavage SpecificityDna CleavageDna Cleavage MechanismDna Topoisomerase Ii InhibitionOligonucleotide ConjugationTopoisomerase Ii InhibitorsTopoisomerase-mediated Dna Breaks
Etoposide and other topoisomerase II-targeted drugs are important anticancer therapeutics. Unfortunately, the safe usage of these agents is limited by their indiscriminate induction of topoisomerase II-mediated DNA cleavage throughout the genome and by a lack of specificity toward cancer cells. Therefore, as a first step toward constraining the distribution of etoposide-induced DNA cleavage sites and developing sequence-specific topoisomerase II-targeted anticancer agents, we covalently coupled the core of etoposide to oligonucleotides centered on a topoisomerase II cleavage site in the PML gene. The initial sequence used for this 'oligonucleotide-linked topoisomerase inhibitor' (OTI) was identified as part of the translocation breakpoint of a patient with acute promyelocytic leukemia (APL). Subsequent OTI sequences were derived from the observed APL breakpoint between PML and RARA. Results indicate that OTIs can be used to direct the sites of etoposide-induced DNA cleavage mediated by topoisomerase IIα and topoisomerase IIβ. OTIs increased levels of enzyme-mediated cleavage by inhibiting DNA ligation, and cleavage complexes induced by OTIs were as stable as those induced by free etoposide. Finally, OTIs directed against the PML-RARA breakpoint displayed cleavage specificity for oligonucleotides with the translocation sequence over those with sequences matching either parental gene. These studies demonstrate the feasibility of using oligonucleotides to direct topoisomerase II-mediated DNA cleavage to specific sites in the genome.
47
A Topoisomerase IIß-Mediated dsDNA Break Required for Regulated Transcription
Bong‐Gun Ju, Victoria V. Lunyak, Valentina Perissi et al. · Science · 2006 · 842 citations
Structural Basis of Type II Topoisomerase Inhibition by the Anticancer Drug Etoposide
Chyuan-Chuan Wu, Tsai‐Kun Li, Lynn Farh et al. · Science · 2011 · 514 citations
Richard Woessner, Michael R. Mattern, Christopher K. Mirabelli et al. · PubMed · 1991 · 462 citations